Spruce Biosciences Common cannot be verified against its exchange. Apparently, Spruce Biosciences is not available for investing at the moment. Please verify the symbol is currently traded on NASDAQ Exchange. If you still believe the symbol you are trying to look up is valid, please let us know, and we will check it as soon as possible.
RefreshSpruce Biosciences Common (SPRB) is listed on NASDAQ Exchange in USA. SPRB conducts business in the Health Care industry (Biotechnology sector). Spruce Biosciences Common sits in the small-cap bucket with market capitalization close to $160.43 million relative to health care companies. Associated fundamentals relevant to market cap include about 2.7 million shares outstanding, operating in the Health Care industry, and enterprise value near $112.26 million. SPRB has 180,537 shares sold short (3.41 days to cover). Spruce Biosciences is an operator in the health care segment where revenue is driven by core operating activity and end-market demand. Spruce Biosciences Common currently holds about $93.3 million in cash as of latest reporting with -$33.33 million of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 3.96. Spruce Biosciences financial stability analysis
Spruce Biosciences, Inc., a biopharmaceutical company, focuses on developing and commercializing novel therapies for rare endocrine disorders. Spruce Biosciences was incorporated in 2014 and is headquartered in Daly City, California. Headquarters are in 611 Gateway Boulevard, South San Francisco, CA, United States, 94080. Recent market snapshot indicates market cap 160.43 million, P/B 3.63. As a micro-cap equity, Spruce Biosciences is evaluated across valuation, solvency, and efficiency signals. Operating metrics are tied to how the market is pricing risk. Price movements may be comparatively less responsive to macroeconomic volatility.
Methodology
Unless otherwise specified, financial data for Spruce Biosciences Common is derived from periodic company reporting (annual and quarterly where available). Asset-level metrics are computed daily by Macroaxis LLC and refreshed regularly based on asset type. Spruce (USA Stocks:SPRB) prices are typically delayed by approximately 20 minutes from primary exchanges for listed equities. Data may be delayed depending on reporting sources and market conventions. All analytics presented are generated using Macroaxis quantitative models that incorporate financial statement analysis, market data, and risk metrics to ensure consistency and comparability. Assumptions: We use public filings and market reference sources with disclosures published by U.S. Securities and Exchange Commission (SEC) via EDGAR as reference inputs. Data may be normalized and can be delayed. All analytics are generated using standardized, rules-based models designed to promote consistency and comparability across instruments. Model assumptions, reference parameters, and selected computational inputs are available in the Model Inputs section. If you have questions about our data sources or methodology, please contact Macroaxis Support.
Analyst Sources
Spruce Biosciences Common may have analyst coverage included in Macroaxis-derived consensus inputs when available. Updates may occur throughout the day.
Editorial review and methodology oversight provided by: Gabriel Shpitalnik, Member of Macroaxis Editorial Board
Spruce Biosciences Related Equities
The peer firms below within the Health Care space frame Spruce Biosciences' pricing and running costs in context. Revenue and margin checks across this group help investors set expectations for Spruce Biosciences' results. Sector-wide trends across this peer group split company-level factors from broader forces.
Spruce Biosciences has a market cap of 160.43 million, current ratio of 9.55. These fundamentals are most informative when tracked over multiple reporting periods. Broader economic conditions can influence Spruce Biosciences Common's company valuation - related indicators include signals in population.Spruce Biosciences currently shows ROE of -109.25%, market cap of USD 160.43 million. Analysis of Spruce Biosciences gains depth when combined with the construction and diversification tools listed below. Spruce Biosciences analysis across multiple dimensions - risk, valuation, diversification - produces a more complete analytical picture. You can also try the Funds Screener module to find actively-traded funds from around the world traded on over 30 global exchanges.
Related Tools for Spruce Stock
Spruce Biosciences volatility profile is best interpreted alongside industry benchmarks.